Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
TMRC
Shinjuku-ku, Tokyo Metropolis, Japantmrc.co.jp ↗
- Ownership
- Private
- Employees
- ~11
- Development stage
- Other
01
Overview
TMRC’s lead program, tamibarotene (TM-411), reached Phase 3 in partnership with Syros Pharmaceuticals for HR-MDS patients overexpressing RARA, but did not meet the primary endpoint. The partnership was terminated in April 2025, with global rights reverting to TMRC. Clinical studies have included acute promyelocytic leukemia, hepatocellular carcinoma, and pediatric indications. TMRC continues to consider next steps based on existing data[3].
- Therapeutic areas
- OncologyHematology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Syros Pharmaceuticals (licensee, terminated 2025)Ohara Pharmaceutical (licensee, pediatric cancer, Japan)Choongwae Pharma Corporation (licensee, South Korea, APL)Oder-Made Souyaku (licensee, China, APL)Children's Hospital Los Angeles (collaboration in neutropenia)
Beyond the preview
Go deeper on TMRC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TMRC.